<code id='ABFD83A455'></code><style id='ABFD83A455'></style>
    • <acronym id='ABFD83A455'></acronym>
      <center id='ABFD83A455'><center id='ABFD83A455'><tfoot id='ABFD83A455'></tfoot></center><abbr id='ABFD83A455'><dir id='ABFD83A455'><tfoot id='ABFD83A455'></tfoot><noframes id='ABFD83A455'>

    • <optgroup id='ABFD83A455'><strike id='ABFD83A455'><sup id='ABFD83A455'></sup></strike><code id='ABFD83A455'></code></optgroup>
        1. <b id='ABFD83A455'><label id='ABFD83A455'><select id='ABFD83A455'><dt id='ABFD83A455'><span id='ABFD83A455'></span></dt></select></label></b><u id='ABFD83A455'></u>
          <i id='ABFD83A455'><strike id='ABFD83A455'><tt id='ABFD83A455'><pre id='ABFD83A455'></pre></tt></strike></i>

          explore

          explore

          author:comprehensive    Page View:9
          Photo illustration based on photograph of The University of Texas MD Anderson Cancer Center in Houston, Texas in 2022
          Photo illustration: STAT; Photo: Adobe

          Three years ago, Jamie Lin, an early-career nephrologist at MD Anderson Cancer Center, made findings that could potentially help both save the kidneys of cancer patients and propel her career as a physician-scientist hoping to one day run her own lab. It was a promising start, but that’s when Lin says one of the Texas institute’s most powerful researchers interfered.

          Lin alleges in a lawsuit that prominent oncologist Padmanee Sharma derailed the publication of papers based on Lin’s work, threatened to undermine her fledgling career, and made defamatory comments about her in retaliation for resisting making Sharma an author on a paper and saying the senior researcher had made no substantial contribution to it.

          advertisement

          “Having this and another paper taken — what would’ve been important papers for my career,” Lin told STAT in an interview. “I’m sure that my career in research has just fallen off a cliff.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          GSK’s asthma push continues as drug succeeds in Phase 3 trials
          GSK’s asthma push continues as drug succeeds in Phase 3 trials

          AkiraSuemori/APAnewasthmatreatmentthatcouldbeadministeredjustonceeverysixmonthshassucceededintwoPhas

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Lawmakers grill UnitedHealth CEO on Change cyberattack

          KentNishimura/GettyImagesOnWednesday,UnitedHealthCEOAndrewWittyappearedbeforeCongresstoanswerforwhat